Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: A meta-analytical evaluation of prospective studies

Journal of the Pancreas

Volumn 14, Issue 6, 2013, Pages 618-625

  Festa, Virginia ^a   Andriulli, Angelo ^b   Valvano, Maria Rosaria ^b   Uomo, Generoso ^c   Perri, Francesco ^b   Andriulli, Nicola ^d   Corrao, Salvatore ^e   Koch, Maurizio ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Drug therapy; Evidence based medicine; Meta analysis as topic; Neoadjuvant therapy; Pancreatic carcinoma; Pancreatic neoplasms; Radiotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION RESPONSE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CHEMORADIOTHERAPY; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84887462960     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035-46.
2. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16:1727-33.
3. National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on October 13, 2011)
4. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7(4):e1000267.
5. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies. Ann Surg Oncol 2012;19:1644-62.
6. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-1900.
7. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
8. Morley PT, Atkins DL, Billi JE, Bossaert L, Callaway CW, de Caen AR, et al. Part 3: Evidence evaluation process: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2010;122 (16 Suppl 2):S283-90.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000,92:205-216.
10. Wilson E.B. Probable inference, the law of succession, and statistical inference. J Am Stat Ass 1927; 22: 209-212.
11. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987; 9:1-30.
12. Higgings JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
15. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and metaregression. Stat Med 2002;21:589-624.
16. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001;5:27-35.
17. Magnin V, Moutardier V, Giovannini MH, Lelong B, Giovannini M, Viret F, et Al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:1300-4.
18. Pipas JM, Barth RJ Jr, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, et al. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005;12:995-1004.
19. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13:1201-8.
20. Le Scodan R, Mornex F, Girard N, Mercier C, Valette PJ, Ychou M, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009;20:1387-96.
21. Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience. Cancer. 2012 Jul 6. doi: 10.1002/cncr.27736. [Epub ahead of print]
22. Small W Jr, Mulcahy MF, Rademaker A, Bentrem DJ, Benson AB, Weitner BB, et Al. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;80:476-82.
23. Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 2011;35:1580-9.
24. Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, et al. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011;149:311-20.
25. Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park DH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderlineresectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012 Jun 6. [Epub ahead of print]
26. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011;150:466-73.
27. Katz MHG, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012 May 17. [Epub ahead of print]
28. Zhang Y, Huang J, Chen M, Jiao LR. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: A meta-analysis. Pancreatology 2012;12:227-33